

**Table 2 - Characteristics of 92 patients treated with first-line fluoropyrimidine**

Characteristic	Frequency
Median age, years (range)	61 (27-77)
<b>Gender</b>	
Male	54
Female	38
<b>PS</b>	
0	65
1	26
2	1
<b>Metastatic site</b>	
Liver	64
Lung	44
Lymph node	27
Peritoneum	19
Ovary	2
Bone	1
<b>Regimens</b>	
5-FU/- LV	70
5-FU continuous infusion	10
UFT/LV	9
UFT	1
TS-1	2
<b>Clinical response</b>	
Complete response	2
Partial response	39
Stable disease	30
Progressive disease	21

PS: Performance status of Eastern Cooperative Oncology Group; 5-FU: 5-fluorouracil; - LV: l-leucovorin; UFT, uracil-tegafur; LV: leucovorin.

### 3.2. Gene expression levels and clinical outcome of patients receiving first-line fluoropyrimidine-based treatment

Median gene expression levels relative to the level of the house-keeping gene  $\beta$ -actin, used as an internal reference, are shown in Table 3. For descriptive purposes, we call gene expressions below the designated cut-point 'low' while those above the designated cut-point are called 'high'. The results of univariate analysis for response and TTP are shown in Table 3. Low TS, low GGH, high RFC1, high MGMT and low cyclin E expression levels were significantly associated with a good response to fluoropyrimidines on univariate analysis ( $P = 0.0030, 0.0250, 0.0120, 0.0030$  and  $0.0020$ , respectively). Low TS, low GGH, high RFC1, low TOPO I, high MGMT, low GSTpi and low cyclin E expression levels significantly correlated with a long TTP in patients given fluoropyrimidine on univariate analysis ( $P = 0.027, 0.023, 0.045, 0.025, 0.039, 0.002$  and  $0.009$ , respectively).

Seventy of the 92 patients given fluoropyrimidines had received 5-FU/LV regimens. Low TS, high FPGS, low GGH, high RFC1, high MGMT and low cyclin E expression levels were significantly associated with a good response to 5-FU/LV on univariate analysis ( $P = 0.0060, 0.0350, 0.0355, 0.0415, 0.0030$  and  $0.0015$ , respectively). Low GGH, low GSTpi, high VEGF and low cyclin E expression levels significantly correlated with a

long TTP in patients given 5-FU/LV on univariate analysis ( $P = 0.016, 0.045, 0.032$  and  $0.003$ , respectively).

### 3.3. Multiple logistic regression analysis of clinical response in patients receiving first-line fluoropyrimidines

Among the expressions of TS, GGH, RFC1, MGMT and cyclin E, which were significantly associated with response as well as TTP in patients given fluoropyrimidines, TS and MGMT expressions continued to be independent predictors of the response to fluoropyrimidines on multiple logistic regression analysis. The clinical responses of patient groups divided according to the cutoff values of TS and MGMT expressions are shown in Table 4. The sensitivity of low TS or high MGMT for the response to fluoropyrimidines (responding patients in the low TS and high MGMT groups/responding patients in all groups) was 0.88, and the specificity of high TS and low MGMT for the response to fluoropyrimidines (non-responding patients in the high TS and low MGMT groups/non-responding patients in all groups) was 0.59. The positive predictive value of low TS or high MGMT for the response to fluoropyrimidines was 0.63, and the negative predictive value of high TS and low MGMT was 0.86. The shortest TTP was observed in the group of patients with TS above and MGMT below the respective cutoff values ( $P = 0.083$ ) (Fig. 1). The median TTP was 5.7 months in patients with low TS or high MGMT and 3.3 months in those with both high TS and low MGMT.

### 3.4. Gene expression levels and clinical outcome of patients receiving second-line CPT-11-based treatment

The results of univariate analyses for response and TTP are shown in Table 5. High TS, high FPGS, low ERCC1, high MGMT, high GSTpi and low VEGF expressions significantly correlated with a good clinical response to second-line CPT-11 treatment ( $P = 0.0085, 0.0145, 0.0015, 0.0215, 0.0155$  and  $0.0165$ , respectively). No significant correlation was demonstrated between any gene expression and TTP for second-line chemotherapy.

## 4. Discussion

Our primary end-point was to clarify the gene expression levels of enzymes involved in the targeting, metabolism or catabolism of fluoropyrimidines, the metabolism or transport of folic acid, DNA-repair systems and drug detoxification systems and thereby identify predictors of clinical outcomes in patients with CRC who receive fluoropyrimidines. The presence of both high TS and low MGMT expression levels was found to be a significant predictor of a poor response to fluoropyrimidine therapy. Clinically, this combination would have an important role in the selection of first-line treatment for CRC with regimens such as FORFIRI (CPT-11/5-FU/LV) or CPT-11 alone.

MGMT is a DNA-repair enzyme that removes alkyl adducts from O<sup>6</sup>-methylguanine. Since the MGMT gene is usually not mutated or deleted in human cancers, loss of MGMT function is probably due mostly to epigenetic changes.<sup>17</sup> Abnormal MGMT activity causes O<sup>6</sup>-methylguanine to accumulate in cellular DNA, potentially resulting in the activation of oncogenes or inactivation of tumour suppressor genes, followed

**Table 3 - Univariate analysis of gene expression levels and clinical outcome (A: response, B: time to progression) in 92 patients treated with first-line fluoropyrimidine-based regimens**

Gene	Number of patients	mRNA expression levels relative to $\beta$ -actin $\times 10^{-3}$ , Median (range)	Cut-point	Bootstrap P-value	RR (%) in low group	RR (%) in high group
<b>A: Correlation between response and gene expression</b>						
TS	92	1.4 (0-10.9)	1.37	0.0030	60.0	29.8
DPD	87	0.22 (0-1.16)	0.48	0.0995	41.3	66.7
FPGS	92	0.49 (0.04-1.69)	0.49	0.1035	36.0	54.8
GGH	91	2.17 (0-9.94)	1.21	0.0250	68.4	38.9
RFC1	92	1.67 (0-8.79)	0.87	0.0120	18.8	50.0
TOPO I	92	1.71 (0-4.93)	1.59	0.1845	53.5	36.7
ERCC1	92	0.41 (0-2.95)	0.38	0.1680	36.4	52.1
MGMT	92	1.75 (0-64.73)	2.59	0.0030	34.3	72.0
GSTpi	92	2.19 (0.48-7.6)	3.71	0.0815	48.2	18.2
EGFR	92	0.86 (0-5.31)	0.48	0.2140	57.9	41.1
VEGF	92	3.85 (0.88-24.3)	4.83	0.2890	40.0	55.6
Cyclin E	92	0.51 (0-2.28)	0.99	0.0020	50.7	13.3
Gene	Number of patients	Cut-point	Bootstrap P-value	Median TTP (day) in low group	Median TTP (day) in high group	
<b>B: Correlation between time to progression (TTP) and gene expression</b>						
TS	92	1	0.027	230	132	
DPD	87	0.31	0.128	141	232	
FPGS	92	0.75	0.293	141	165	
GGH	91	4.87	0.023	151	64	
RFC1	92	0.87	0.045	68	155	
TOPO I	92	2.68	0.025	155	105	
ERCC1	92	0.6	0.296	137	165	
MGMT	92	3.22	0.039	134	253	
GSTpi	92	2.47	0.002	169	86	
EGFR	92	0.6	0.161	148	141	
VEGF	92	7.06	0.108	141	232	
Cyclin E	92	1.09	0.009	155	57	

**Table 4 - Predictive value of TS, MGMT and their combination for the response to fluoropyrimidine (TS and MGMT were selected as independent variables in multiple logistic regression analysis)**


Gene expression status	Number of non-responding patients	Number of responding patients	RR (%)	P-value ( $\chi^2$ -test)
All	51	41	44.6	-
Low MGMT	44	23	34.3	0.0012
High MGMT	7	18	72.0	
Low TS	18	27	60.0	0.0036
High TS	33	14	29.8	
High MGMT or low TS	21	36	63.2	<.0001
Low MGMT and high TS	30	5	14.3	

TS: thymidylate synthase, MGMT: O<sup>6</sup>-methylguanine-DNA methyltransferase.

by carcinogenesis.<sup>17-20</sup> In previous studies, the significance of the correlation between MGMT promoter hypermethylation or loss of MGMT expression and patients' prognosis was controversial,<sup>21-25</sup> and its prognostic value for patients treated with specific regimens of anticancer agents remains a matter of debate.

As for CRC, abnormal MGMT expression has been examined in many studies in connection with microsatellite insta-

bility (MSI) or CpG island methylator phenotype (CIMP).<sup>25-27</sup> Kohonen-Corish and colleagues reported that low-MSI characterised a distinct subgroup of patients with stage C colon cancer who had poor outcomes.<sup>25</sup> They also found that loss or reduced MGMT protein expression was associated with the low-MSI phenotype, but was not a prognostic factor for overall survival in colon cancer.<sup>25</sup> Recent studies have shown that 5-FU-based adjuvant chemotherapy improves overall



**Fig. 1 – Time to progression in patients given fluoropyrimidines according to the cutoff levels of TS and MGMT expression ( $p = 0.083$ ). TS: thymidylate synthase, MGMT: O<sup>6</sup>-methylguanine-DNA methyltransferase.**

survival in patients who have non-high-MSI CRC as compared with those who have high-MSI CRC.<sup>28,29</sup> On the other hand, Nagasaka and colleagues reported that the later the tumour stage at diagnosis, the less likely MGMT promoter will be

methylated; in addition, the recurrence rate associated with oral fluoropyrimidine-based adjuvant chemotherapy was significantly higher in patients with unmethylated MGMT than in those with methylated MGMT (not adjusted for MSI status).<sup>27</sup> To date, the value of MGMT as a prognostic or predictive marker for fluoropyrimidines remains controversial. In this study, MGMT expression was found to be the most significant biomarker for the response to fluoropyrimidines. Furthermore, MGMT combined with TS, one of the most promising enzymes for predicting clinical outcomes of fluoropyrimidine treatment, was shown to be a powerful predictor of the response to fluoropyrimidines.<sup>1,30</sup>

In the subset analysis of 70 patients who received 5-FU/LV as first-line chemotherapy, three enzymes involved in the formation, degradation and transfer into cells of folates, i.e. FPGS, GGH and RFC1, were significantly related to response and TTP. It suggests that high FPGS, low GGH and high RFC1 activity promotes optimal modulation of 5-FU by LV, probably by augmenting the retention of high levels of reduced polyglutamated folates in tumours. We also investigated the predictive value of gene expression levels in patients who received second-line CPT-11-based chemotherapy. Ideally, predictive markers should be evaluated by large prospective randomised trials in patients receiving first-line chemotherapy, and our results suggested that TS, FPGS, ERCC1, MGMT,

**Table 5 – Univariate analysis of gene expression levels and clinical outcome (A: response, B: time to progression) in 63 patients treated with second-line CPT-11-based regimens**

Gene	Number of patients	Cut-point	Bootstrap P-value	RR (%) in low group	RR (%) in high group
<b>A: Correlation between response and gene expression</b>					
TS	63	1.43	0.0085	5.7	25.0
DPD	60	0.42	0.4735	11.5	25.0
FPGS	63	0.83	0.0145	10.9	37.5
GGH	62	1.1	0.2390	0.0	15.4
RFC1	63	0.77	0.3420	28.6	12.5
TOPO I	63	2.13	0.1630	10.6	25.0
ERCC1	63	0.11	0.0015	44.4	9.3
MGMT	63	1.74	0.0215	6.3	22.6
GSTpi	63	2.43	0.0155	5.3	28.0
EGFR	63	0.39	0.0810	33.3	11.1
VEGF	63	1.97	0.0165	37.5	10.9
Cyclin E	63	1.02	0.056	11.1	33.3
Gene	Number of patients	Cut-point	Bootstrap P- value	Median TTP (day) in low group	Median TTP (day) in high group
<b>B: Correlation between time to progression (TTP) and gene expression</b>					
TS	63	1.38	0.089	97	103
DPD	60	0.14	0.231	99	102
FPGS	63	0.35	0.096	151	98
GGH	62	1.04	0.058	57	102
RFC1	63	1.32	0.221	103	98
TOPO I	63	2.71	0.100	98	113
ERCC1	63	0.11	0.465	119	99
MGMT	63	1.64	0.086	87	110
GSTpi	63	2.89	0.060	92	155
EGFR	63	0.39	0.119	118	98
VEGF	63	2.78	0.243	151	92
Cyclin E	63	0.78	0.321	87	113

TS: thymidylate synthase, DPD: dihydropyrimidin dehydrogenase, FPGS: folylpolyglutamate synthetase, GGH:  $\gamma$ -glutamyl hydrolase, RFC1: reduced folate carrier 1, TOPO I: DNA topoisomerase I, ERCC1: excision repair cross-complementing 1, MGMT: O<sup>6</sup>-methylguanine-DNA methyltransferase, GSTpi: glutathione S-transferase pi, EGFR: epidermal growth factor receptor, VEGF: vascular endothelial growth factor.

GSTpi and VEGF are candidate genes for the prediction of the response to CPT-11.

On the other hand, the methodologies in this study to evaluate mRNA levels in the primary tumours with real time RT-PCR offered several advantages. It can easily overcome problems associated with sample volume and tumour heterogeneity by obtaining specimens from primary tumours by laser-captured microdissection. Furthermore, formalin-fixed, paraffin-embedded specimens of the primary tumours are obtained from nearly all patients with CRC. However, only a few studies have examined the relation between levels of molecular markers in primary colorectal tumours and associated metastases.<sup>10,31,32</sup> Since we analysed samples from primary tumours to predict the response of metastatic lesions to chemotherapy, the clinical value of our technique must be validated in larger prospective studies. In addition, we should bear in mind that all patients in our study were Japanese. The potential importance of ethnicity in studies of gene expressions should be taken into account in prospective clinical trials in the future.

Our findings suggest that the presence of both high TS and low MGMT expression is a significant predictor of a poor response to fluoropyrimidine treatment, and the diagnostic value of these predictive markers should be validated in larger cohorts of patients. Furthermore, future studies should also evaluate predictive markers for chemotherapy in patients who receive oxaliplatin-based or CPT-11-based regimens as first-line treatment. A combined analysis of these results might provide new insights into the optimal design for randomised clinical trials.

### Conflicts of interest statement

Yoshihiro Okayama and Toshinori Oka are employees of Optimal Medication Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.

### Acknowledgements

The authors thank Professor Peter V. Danenberg, University of Southern California/Norris Comprehensive Cancer Center, Ms Kathleen Danenberg, Response Genetics Inc., Los Angeles, and Dr. Masakazu Fukushima, Taiho Pharmaceutical Co., Ltd., Japan, for their helpful comments on this manuscript.

This research was funded by TAIHO Pharmaceutical Co., who is acknowledged for the study design and the statistical analysis.

### REFERENCES

- Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. *Clin Cancer Res* 2000;6(4):1322-7.
- Metzger R, Danenberg K, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. *Clin Cancer Res* 1998;4(10):2371-6.
- Ichikawa W, Uetake H, Shiota Y, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. *Br J Cancer* 2003;89(8):1486-92.
- Sohn KJ, Smirnakis F, Moskovitz DN, et al. Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. *Gut* 2004;53(12):1825-31.
- Chazal M, Cheradame S, Formento JL, et al. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. *Clin Cancer Res* 1997;3(4):553-7.
- Shiota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. *J Clin Oncol* 2001;19(23):4298-304.
- Del Rio M, Molina F, Bascoul-Molleivi C, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. *J Clin Oncol* 2007;25(7):773-80.
- Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. *Cancer Res* 1995;55(10):2116-21.
- Goto S, Kamada K, Soh Y, Ihara Y, Kondo T. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. *Jpn J Cancer Res* 2002;93(9):1047-56.
- Vallbohmer D, Iqbal S, Yang DY, et al. Molecular determinants of irinotecan efficacy. *Int J Cancer* 2006;119(10):2435-42.
- Schneider S, Park DJ, Yang D, et al. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. *Pharmacogenet Genomics* 2006;16(8):555-63.
- Bonner RF, Emmert-Buck M, Cole K, et al. Laser capture microdissection: molecular analysis of tissue. *Science* 1997;278(5342):1481,3.
- Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. *J Gastrointest Surg* 2000;4(2):135-42.
- Miller R, Siegmund D. Maximally selected  $X^2$  statistics. *Biometrics* 1982;38:1011-6.
- Halpern J. Maximally selected  $X^2$  statistics for smaller samples. *Biometrics* 1982;38:1017-23.
- Lausen B, Schumacher M. Maximally selected rank statistics. *Biometrics* 1992;48:73-85.
- Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O<sup>6</sup>-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. *Cancer Res* 2000;60(9):2368-71.
- Ishibashi T, Nakabeppu Y, Sekiguchi M. Artificial control of nuclear translocation of DNA repair methyltransferase. *J Biol Chem* 1994;269(10):7645-50.
- Mitra G, Pauly GT, Kumar R, et al. Molecular analysis of O<sup>6</sup>-substituted guanine-induced mutagenesis of ras oncogenes. *Proc Natl Acad Sci USA* 1989;86(22):8650-4.
- Challen C, Lunec J, Warren W, Collier J, Bassendine MF. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. *Hepatology* 1992;16(6):1362-6.
- Esteller M, Gaidano G, Goodman SN, et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA

- methyltransferase and survival of patients with diffuse large B-cell lymphoma. *J Natl Cancer Inst* 2002;94(1):26-32.
22. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. *New Engl J Med* 2000;343(19):1350-4.
  23. Matsukura S, Miyazaki K, Yakushiji H, et al. Expression and prognostic significance of O<sup>6</sup>-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. *Ann Surg Oncol* 2001;8(10):807-16.
  24. Brock MV, Gou M, Akiyama Y, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. *Clin Cancer Res* 2003;9(8):2912-9.
  25. Kohonen-Corish MR, Daniel JJ, Chan C, et al. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. *J Clin Oncol* 2005;23(10):2318-24.
  26. Ogino S, Meyerhardt JA, Kawasaki T, et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. *Virchows Arch* 2007;450(5):529-37.
  27. Nagasaka T, Sharp GB, Notohara K, et al. Hypermethylation of O<sup>6</sup>-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. *Clin Cancer Res* 2003;9(14):5306-12.
  28. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *New Engl J Med* 2003;349(3):247-57.
  29. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. *Gastroenterology* 2004;126(2):394-401.
  30. Ichikawa W, Uetake H, Shiota Y, et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. *Clin Cancer Res* 2003;9(2):786-91.
  31. Shiota Y, Ichikawa W, Uetake H, Yamada H, Nihei Z, Sugihara K. Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. *Ann Surg Oncol* 2002;9(6):599-603.
  32. Kuramochi H, Hayashi K, Uchida K, et al. 5-Fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. *Int J Cancer* 2006;119(3):522-6.

## Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil

Takako Eguchi Nakajima<sup>1,2</sup>, Masahiro Yasunaga<sup>2</sup>, Yasuhiko Kano<sup>3</sup>, Fumiaki Koizumi<sup>4</sup>, Ken Kato<sup>1</sup>, Tetsuya Hamaguchi<sup>1</sup>, Yasuhide Yamada<sup>1</sup>, Kuniaki Shirao<sup>1</sup>, Yasuhiro Shimada<sup>1</sup> and Yasuhiro Matsumura<sup>2\*</sup>

<sup>1</sup>Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan

<sup>2</sup>Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

<sup>3</sup>Hematology Oncology, Tochigi Cancer Center, Tochigi, Japan

<sup>4</sup>Shien Lab Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

The authors reported in a previous study that NK012, a 7-ethyl-10-hydroxy-camptothecin (SN-38)-releasing nano-system, exhibited high antitumor activity against human colorectal cancer xenografts. This study was conducted to investigate the advantages of NK012 over irinotecan hydrochloride (CPT-11) administered in combination with 5-fluorouracil (5FU). The cytotoxic effects of NK012 or SN-38 (an active metabolite of CPT-11) administered in combination with 5FU was evaluated *in vitro* in the human colorectal cancer cell line HT-29 by the combination index method. The effects of the same drug combinations was also evaluated *in vivo* using mice bearing HT-29 and HCT-116 cells. All the drugs were administered i.v. 3 times a week; NK012 (10 mg/kg) or CPT11 (50 mg/kg) was given 24 hr before 5FU (50 mg/kg). Cell cycle analysis in the HT-29 tumors administered NK012 or CPT-11 *in vivo* was performed by flow cytometry. NK012 exerted more synergistic activity with 5FU compared to SN-38. The therapeutic effect of NK012/5FU was significantly superior to that of CPT-11/5FU against HT-29 tumors ( $p = 0.0004$ ), whereas no significant difference in the antitumor effect against HCT-116 tumors was observed between the 2-drug combinations ( $p = 0.2230$ ). Cell-cycle analysis showed that both NK012 and CPT-11 tend to cause accumulation of cells in the S phase, although this effect was more pronounced and maintained for a more prolonged period with NK012 than with CPT-11. Optimal therapeutic synergy was observed between NK012 and 5FU, therefore, this regimen is considered to hold promise of clinical benefit, especially for patients with colorectal cancer.

© 2008 Wiley-Liss, Inc.

**Key words:** NK012; SN-38; 5-fluorouracil; drug delivery system; colorectal cancer

The 5-year survival rates of colorectal cancer (CRC) have improved remarkably over the last 10 years, accounted for in large part by the extensively investigated agents after 5-fluorouracil (5FU). Irinotecan hydrochloride (CPT-11), a water-soluble, semi-synthetic derivative of camptothecin, is one such agent that has been shown to be highly effective, and currently represents a key-drug in first- and second-line treatment regimens for CRC. CPT-11 monotherapy, however, has not been shown to yield superior efficacy, including in terms of the median survival time, to bolus 5FU/leucovorin (LV) alone.<sup>1</sup> In 2 Phase III trials, the addition of CPT-11 to bolus or infusional 5FU/LV regimens clearly yielded greater efficacy than administration of 5FU/LV alone, with a doubling of the tumor response rate and prolongation of the median survival time by 2–3 months.<sup>1,2</sup>

CPT-11 is converted to 7-ethyl-10-hydroxy-camptothecin (SN-38), a biologically active and water-insoluble metabolite of CPT-11, by carboxylesterases in the liver and the tumor. SN-38 has been demonstrated to exhibit up to a 1,000-fold more potent cytotoxic activity than CPT-11 against various cancer cells *in vitro*.<sup>3</sup> The metabolic conversion rate is, however, very low, with only <10% of the original volume of CPT-11 being metabolized to SN-38<sup>4,5</sup>; conversion of CPT-11 to SN-38 also depends on genetic interindividual variability of the activity of carboxylesterases.<sup>6</sup>

Direct use of SN-38 itself for clinical cancer treatment must be shown to be identical in terms of both efficacy and toxicity.

Some drugs incorporated in drug delivery systems (DDS), such as Abraxane and Doxil, are already in clinical use.<sup>7,8</sup> The clinical benefits of DDS are based on their EPR effect.<sup>9</sup> The EPR effect is based on the pathophysiological characteristics of solid tumor tissues: hypervascularity, incomplete vascular architecture, secretion of vascular permeability factors stimulating extravasation within cancer tissue, and absence of effective lymphatic drainage from the tumors that impedes the efficient clearance of macromolecules accumulated in solid tumor tissues. Several types of DDS can be used for incorporation of a drug. A liposome-based formulation of SN-38 (LE-SN38) has been developed, and a clinical trial to assess its efficacy is now under way.<sup>10,11</sup>

Recently, we demonstrated that NK012, novel SN-38-incorporating polymeric micelles, exerted superior antitumor activity and less toxicity than CPT-11.<sup>12</sup> NK012 is characterized by a smaller size of the particles than LE-SN38; the mean particle diameter of NK012 is 20 nm. NK012 can release SN-38 under neutral conditions even in the absence of a hydrolytic enzyme, because the bond between SN-38 and the block copolymer is a phenol ester bond, which is stable under acidic conditions and labile under mild alkaline conditions. The release rate of SN-38 from NK012 under physiological conditions is quite high; more than 70% of SN-38 is released within 48 hr. We speculated that the use of NK012, in place of CPT-11, in combination with 5FU may yield superior results in the treatment of CRC. In the present study, we evaluated the antitumor activity of NK012 administered in combination with 5FU as compared to that of CPT-11 administered in combination with 5FU against CRC in an experimental model.

### Material and methods

#### Cells and animals

The human colorectal cancer cell lines used, namely, HT-29 and HCT-116, were purchased from the American Type Culture Collection (Rockville, MD). The HT-29 cells and HCT-116 cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Cell Culture Technologies, Gaggenu-Hoerden, Germany), penicillin, streptomycin, and amphotericin B (100 units/mL, 100 µg/mL, and 25 µg/mL, respectively; Sigma, St. Louis, MO) in a humidified atmosphere containing 5% CO<sub>2</sub> at 37°C.

BALB/c *nu/nu* mice were purchased from SLC Japan (Shizuoka, Japan). Six-week-old mice were subcutaneously (s.c.)

\*Correspondence to: Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. Fax: +81-4-7134-6866. E-mail: yhmatsum@east.ncc.go.jp

Received 2 September 2007; Accepted after revision 20 November 2007  
DOI 10.1002/ijc.23381

Published online 14 January 2008 in Wiley InterScience (www.interscience.wiley.com).

inoculated with  $1 \times 10^6$  cells of HT-29 or HCT-116 cell line in the flank region. The length ( $a$ ) and width ( $b$ ) of the tumor masses were measured twice a week, and the tumor volume (TV) was calculated as follows:  $TV = (a \times b^2)/2$ . All animal procedures were performed in compliance with the Guidelines for the Care and Use of Experimental Animals established by the Committee for Animal Experimentation of the National Cancer Center; these guidelines meet the ethical standards required by law and also comply with the guidelines for the use of experimental animals in Japan.

#### Drugs

The SN-38-incorporating polymeric micelles, NK012, and SN-38 were prepared by Nippon Kayaku (Tokyo, Japan).<sup>12</sup> CPT-11 was purchased from Yakult Honsha (Tokyo, Japan). 5FU was purchased from Kyowa Hakko (Tokyo, Japan).

#### Cell growth inhibition assay

HT-29 cells were seeded in 96-well plates at a density of 2,000 cells/well in a final volume of 90  $\mu$ L. Twenty-four hours after seeding, a graded concentration of NK012 or SN-38 was added concurrently with 5FU to the culture medium of the HT-29 cells in a final volume of 100  $\mu$ L for drug interaction studies. The culture was maintained in the CO<sub>2</sub> incubator for an additional 72 hr. Then, cell growth inhibition was measured by the tetrazolium salt-based proliferation assay (WST assay; Wako Chemicals, Osaka, Japan). WST-1 labeling solution (10  $\mu$ L) was added to each well and the plates were incubated at 37°C for 3 hr. The absorbance of the formazan product formed was detected at 450 nm in a 96-well spectrophotometric plate reader. Cell viability was measured and compared to that of the control cells. Each experiment was carried out in triplicate and was repeated at least 3 times. Data were averaged and normalized against the nontreated controls to generate dose-response curves.

#### Drug interaction analysis

The nature of interaction between NK012 or SN-38 and 5FU against HT-29 cells was evaluated by median-effect plot analyses and the combination index (CI) method of Chou and Talalay.<sup>13</sup> Data analysis was performed using the Calcsyn software (Bio-soft, NY, USA). NK012 or SN-38 was combined with 5FU at a fixed ratio that spanned the individual IC<sub>50</sub> values of each drug. The IC<sub>50</sub> values were determined on the basis of the dose-response curves using the WST assay. For any given drug combination, the CI is known to represent the degree of synergy, additivity or antagonism. It is expressed in terms of fraction-affected ( $F_a$ ) values, which represents the percentage of cells killed or inhibited by the drug. Isobologram equations and  $F_a/CI$  plots were constructed by computer analysis of the data generated from the median effect analysis. Each experiment was performed in triplicate with 6 gradations and was repeated at least 3 times. The resultant dose-response curves were averaged, to create a single composite dose-response curve for each combination.

#### In vivo analysis of the effects of NK012 combined with 5FU as compared to those of CPT-11 combined with 5FU

When the mean tumor volumes reached  $\sim 93$  mm<sup>3</sup>, the mice were randomly divided into test groups consisting of 5 mice per group (Day 0). The drugs were administered i.v. via the tail vein of the mice. In the groups administered NK012 or 5FU as single agents, the drug was administered on Days 0, 7 and 14. In the combined treatment groups, NK012 or CPT-11 was administered 24 hr before 5FU on Days 0, 7 and 14, according to the previously reported combination schedule for CPT-11 and 5FU.<sup>14</sup> Complete response (CR) was defined as tumor not detectable by palpation at 90 days after the start of treatment, at which time-point the mice were sacrificed. Tumor volume and body weight were measured twice a week. As a general rule, animals in which the tumor volume exceeded 2,000 mm<sup>3</sup> were also sacrificed.

*Experiment 1. Evaluation of the effects of NK012 combined with 5FU and determination of the maximum tolerated dose (MTD) of NK012/5FU.* By comparing the data between NK012 administered as a single agent and NK012/5FU, we evaluated the effects of the combined regimen against the s.c HT-29 tumors. A preliminary experiment showed that combined administration of NK012 15 mg/kg + 5FU 50 mg/kg every 6 days caused drug-related lethality (data not shown). To determine the MTD, therefore, we set the dosing schedule of the combined regimen at 5 or 10 mg/kg of NK012 + 50 mg/kg of 5FU three times a week.

*Experiment 2. Comparison of the antitumor effect of NK012/5FU and CPT-11/5FU.* Based on a comparison of the data between NK012/5FU and CPT-11/5FU against the s.c HT-29 and HCT-116 tumors, we investigated the feasibility of the clinical application of NK012/5FU for the treatment of CRC. CPT-11/5FU was administered three times a week at the respective MTDs of the 2 drugs as previously reported, that is, CPT11 at 50 mg/kg and 5FU at 50 mg/kg, respectively.<sup>14</sup> NK012/5FU was administered once three times a week at the respective MTDs of the 2 drugs determined from Experiment 1.

#### Cell cycle analysis

Samples from the HT-29 tumors that had grown to 80–100 mm<sup>3</sup> were removed from the mice at 6, 24, 48, 72 and 96 hr after the administration of NK012 alone at 10 mg/kg or CPT-11 alone at 50 mg/kg. The samples were excised, minced in PBS and fixed in 70% ethanol at  $-20^\circ\text{C}$  for 48 hr. They were then digested with 0.04% pepsin (Sigma chemical Co., St Louis, MO) in 0.1 N HCL for 60 min at 37°C in a shaking bath to prepare single-nuclei suspensions. The nuclei were then centrifuged, washed twice with PBS and stained with 40  $\mu$ g/mL of propidium iodide (Molecular Probes, OR) in the presence of 100  $\mu$ g/mL RNase in 1 mL PBS for 30 min at 37°C. The stained nuclei were analyzed with B-D FACSCalibur (BD Biosciences, San Jose, CA), and the cell cycle distribution was analyzed using the Modfit program (Verity Software House Topsham, ME).

#### Statistical analyses

Data were expressed as mean  $\pm$  SD. Data were analysed with Student's  $t$  test when the groups showed equal variances ( $F$  test), or Welch's test when they showed unequal variances ( $F$  test).  $p < 0.05$  was regarded as statistically significant. All statistical tests were 2-sided.

#### Results


##### Antiproliferative effects of NK012 or SN-38 administered in combination with 5FU

Figure 1a shows the dose-response curves for NK012 alone, 5FU alone and a combination of the two. The IC<sub>50</sub> levels of NK012 and 5FU against the HT-29 cells were 39 nM and 1  $\mu$ M, respectively, and the IC<sub>50</sub> level of SN-38 was 14 nM (data not shown). Based on these data, the molar ratio of NK012 or SN-38:5FU of 1:1,000 was used for the drug combination studies.

Figures 1b and 1c show the median-effect and the combination index plots. Combination indices (CIs) of  $<1.0$  are indicative of synergistic interactions between 2 agents; additive interactions are indicated by CIs of 1.0, and antagonism by CIs of  $>1.0$ . Figure 1c shows the combination index for NK012 and 5FU, when 2 drugs are supposed to be mutually exclusive. Marked synergism was observed between  $F_a$  0.2 and 0.6. Theoretically, the CI method is the most reliable around an  $F_a$  of 0.5, suggesting synergistic effects of the combination of NK012 and 5FU. This synergistic effect was more evident than that of SN-38/5FU (Fig. 1d).

##### In vivo effect of combined NK012 and 5FU

*Experiment 1. Dose optimization and effect of combined NK012 and 5FU against HT-29 tumors.* Comparison of the relative tumor volumes on Day 40 revealed significant differences between



**FIGURE 1** – Interaction of NK012 and 5FU *in vitro*. (a) Dose-response curves for NK012 alone (■), 5FU alone (▲) and their combination (□) against HT-29 cells. HT-29 cells were seeded at 2,000 cells/well. Twenty-four hours after seeding, a graded concentration of NK012 or 5FU was added to the culture medium of the HT-29 cells. Cell growth inhibition was measured by WST assay after 72 hr of treatment. Cell viability was measured and compared with that of the control cells. Each experiment was carried out independently and repeated at least 3 times. Points, mean of triplicates; bars, SD. (b) Median effect plot for the interaction of NK012 and 5FU. (c, d) Combination index for the interaction as a function of the level of effect (fraction effect = 0.5 is the  $IC_{50}$ ). The straight line across the CI value of 1.0 indicates additive effect and CIs above and below indicate antagonism and synergism, respectively. The molar ratio of NK012/5FU (c) or SN-38/5FU (d) at 1:1,000 was tested by CI analysis. Black circles represent the CIs of the actual data points, solid lines represent the computer-derived CIs at effect levels ranging from 10 to 100% inhibition of cell growth, and the dotted lines represent the 95% confidence intervals.

those in the mice administered NK012 alone and those administered NK012/5FU at 5 mg/kg of NK012 ( $p = 0.018$ ) (Fig. 2a). Although there was no statistically significant difference in the relative tumor volume measured on Day 54 between the mice administered NK012 alone and NK012/5FU at 10 mg/kg of NK012 ( $p = 0.3050$ ), a trend of superior antitumor effect was demonstrated in the group treated with NK012/5FU at 10 mg/kg of NK012 (Fig. 2a). The CR rates were 20, 40 and 60% for 5 mg/kg NK012 + 50 mg/kg 5FU, 10 mg/kg NK012 alone and 10 mg/kg NK012 + 50 mg/kg 5FU, respectively. The schedule of 10 mg/kg NK012 + 50 mg/kg 5FU resulted in no remarkable toxicity in terms of body weight changes, and these doses were determined as representing the MTDs (Fig. 2b).

**Experiment 2. Comparison of the antitumor effect of combined NK012/5FU and CPT-11/5FU against HT-29 and HCT-116 tumors.** The therapeutic effect of NK012/5FU on Day 60 was significantly superior to that of CPT-11/5FU against the HT-29 tumors ( $p = 0.0004$ ) (Fig. 3a). A more potent antitumor effect, namely, a 100% CR rate, was obtained in the NK012/5FU group as compared to the 0% CR rate in the CPT-11/5FU group. Although no statistically significant difference in the relative tumor volume on Day 61 was demonstrated between the NK012/

5FU and CPT-11/5FU in the case of the HCT-116 tumors ( $p = 0.2230$ ), a trend of superior antitumor effect against these tumors was observed in the NK012/5FU treatment group (Fig. 3b). The CR rates for the case of the HCT-116 tumors were 0% in both NK012/5FU and CPT-11/5FU groups.


#### Specificity of cell cycle perturbation

We studied the differences in the effects between NK012 10 mg/kg and CPT-11 50 mg/kg on the cell cycle (Fig. 4a). The data indicated that both NK012 and CPT-11 tended to cause accumulation of cells in the S phase, although the effect of NK012 was stronger and maintained for a more prolonged period than that of CPT-11; the maximal percentage of S-phase cells in the total cell population in the tumors was 34% at 24 hr after the administration of CPT-11, whereas it was 39% at 48 hr after the administration of NK012 (Figs. 4b, and 4c).

#### Discussion

Our primary endpoint was to clarify the advantages of NK012 over CPT-11 administered in combination with 5FU. We demonstrated that combined NK012 and 5FU chemotherapy exerts more






**FIGURE 2** – Effect of NK012 alone or NK012 in combination with 5FU against HT-29 tumor-bearing mice. Points, mean; bars, SD. (a) Antitumor effect of each regimen on Days 0, 7 and 14. (○) control, (□) 5FU 50 mg/kg alone, (◇) NK012 5 mg/kg alone, (◆) NK012 5 mg/kg 24 hr before 5FU 50 mg/kg, (△) NK012 10 mg/kg alone, (▲) NK012 10 mg/kg 24 hr before 5FU 50 mg/kg. (b) Changes in the relative body weight. Data were derived from the same mice as those used in the present study.

synergistic activity *in vitro* and significantly greater antitumor activity against human CRC xenografts as compared to CPT-11/5FU. The combination of NK012 and 5FU is considered to hold promise of clinical benefit for patients with CRC.

CPT-11, a topoisomerase-I inhibitor, and 5FU, a thymidilate synthase inhibitor, have been demonstrated to be effective agents for the treatment of CRC. A combination of these 2 drugs has also been demonstrated to be clearly more effective than either CPT-11 or 5FU/LV administered alone *in vivo* and in clinical settings.<sup>1,2,14</sup> Administration of 5FU by infusion with CPT-11 was shown to be associated with reduced toxicity and an apparent improvement in survival as compared to that of administration of the drug by bolus injection with CPT-11.<sup>1,2</sup> This synergistic enhancement may result from the mechanism of action of the 2 drugs; CPT-11 has been reported to cause accumulation of cells in the S phase, and 5FU infusion is known to cause DNA damage specifically in cells of the S phase.<sup>14</sup> On the basis of this background, our results suggesting the more pronounced and more prolonged accumulation of the tumor cells in the S phase caused by NK012 as compared with that by CPT-11 may explain the more effective synergy of the former administered with 5FU infusion.



**FIGURE 3** – Effect of NK012/5FU as compared with that of CPT11/5FU against HT-29 (a) or HCT-116 (b) tumor-bearing mice. Antitumor effect of each schedule on Days 0, 7 and 14. (○) control, (×) CPT-11 50 mg/kg 24 hr before 5FU 50 mg/kg, (△) NK012 10 mg/kg 24 hr before 5FU 50 mg/kg. Points, mean; bars, SD.

This may be attributable to accumulation of NK012 due to the enhanced permeability and retention (EPR) effect.<sup>9</sup> It is also speculated that NK012 allows sustained release of free SN-38, which may move more freely in the tumor interstitium.<sup>15</sup> Otherwise NK012 itself could internalize into cells to localize in several cytoplasmic organelles as reported by Savic *et al.*<sup>16</sup> These characteristics of NK012 may be responsible for its more potent antitumor activity observed in this study, because CPT-11 has been reported to show time-dependent growth-inhibitory activity against the tumor cells.<sup>17</sup>

The major dose-limiting toxicities of CPT-11 are diarrhea and neutropenia. SN-38, the active metabolite of CPT-11, may cause CPT-11-related diarrhea as a result of mitotic -inhibitory activity.<sup>18</sup> Because it undergoes significant biliary excretion, SN-38 may have a potentially long residence time in the gastrointestinal tract that may be associated with prolonged diarrhea.<sup>19,20</sup> In our previous report, we evaluated the tissue distribution of SN-38 after administration of an equimolar amount of NK012 (20 mg/kg) and CPT-11 (30 mg/kg), and found no difference in the level of SN-38 accumulation in the small intestine.<sup>12</sup> A significant antitumor effect of NK012 with a lower incidence of diarrhea was also dem-




FIGURE 4 – Cell cycle analysis of HT-29 tumor cells collected 24, 48, 72 and 96 hr after administration of NK012 at 10 mg/kg alone or CPT-11 at 50 mg/kg alone using the Modfit program (Verity Software House Topsham, ME). (a) Cell cycle analysis of HT-29 tumor cells 24 and 96 hr after administration of NK012 at 10 mg/kg or CPT-11 at 50 mg/kg, respectively. (b) Cell cycle distribution of tumor cells 0, 24, 48, 72 and 96 hr after treatment with NK012 at 10 mg/kg. (c) Cell cycle distribution of tumor cells 0, 24, 48, 72 and 96 hr after treatment with CPT-11 at 50 mg/kg.

onstrated as compared to that observed with CPT-11 in a rat mammary tumor model.<sup>21</sup> Combined administration of CPT-11 with 5FU/LV infusion appears to be associated with acceptable toxicity in patients with CRC. In addition, no significant difference in the frequency of Grade 3/4 diarrhea was noted between patients

treated with FOLFIRI (CPT-11 regimen with bolus and infusional 5FU/LV) and those treated with FOLFOX6 (oxaliplatin regimen with bolus and infusional 5FU/LV).<sup>22,23</sup> Our *in vivo* data actually revealed no severe body weight loss in the NK012/5FU group. Consequently, we expect that the NK012/5FU regimen, especially

with infusional 5FU, may be an attractive arm for a Phase III trial in CRC, with CPT-11/5FU as the control arm. We have already initiated a Phase I trial of NK012 in patients with advanced solid tumors based on the data suggesting higher efficacy and lower toxicity of this preparation than CPT-11 *in vivo*.<sup>12</sup>

In conclusion, we demonstrated that combined NK012 and 5FU chemotherapy exerts significantly greater antitumor activity against human CRC xenografts as compared to CPT-11/5FU, indicating the necessity of clinical evaluation of this combined regimen.

## References

1. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. *Oncologist* 2001;6:81–91.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 2000;355:1041–7.
3. Takimoto CH, Arbuck SG. Topoisomerase I targeting agents: the camptothecins. In: Chabner BA, Lango DL, eds. *Cancer chemotherapy and biotechnology: principal and practice*, 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2001. 579–646.
4. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. *Drug Metab Dispos* 2000;28:423–33.
5. Rothenberg ML, Kuhn JG, Burris HA, III, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD. Phase I and pharmacokinetic trial of weekly CPT-11. *J Clin Oncol* 1993;11:2194–204.
6. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, Selves J, Chatelut E, Bugat R, Canal P. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. *Br J Cancer* 1999;80:364–70.
7. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* 2005;23:7794–803.
8. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. *Curr Oncol Rep* 2001;3:156–62.
9. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumorotropic accumulation of proteins and the antitumor agent smancs. *Cancer Res* 1986;46:6387–92.
10. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, Ahmad I. Development and characterization of a novel liposome-based formulation of SN-38. *Int J Pharm* 2004;270:93–107.
11. Kraut EH, Fishman MN, LoRusso PM, Gorden MS, Rubin EH, Haas A, Fetterly GJ, Cullinan P, Dul JL, Steinberg JL. Final result of a phase I study of liposome encapsulated SN-38 (LE-SN38): safety, pharmacogenomics, pharmacokinetics, and tumor response [abstract 2017]. *Proc Am Soc Clin Oncol* 2005;23:139S.
12. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, Matsumura Y. Novel SN-38-incorporating polymeric micelles. NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. *Cancer Res* 2006;66:10048–56.
13. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv Enzyme Regul* 1984;22:27–55.
14. Azrak RG, Cao S, Slocum HK, Toth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. *Clin Cancer Res* 2004;10:1121–9.
15. Jain RK. Barriers to drug delivery in solid tumors. *Sci Am* 1994;271:58–65.
16. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. *Science* 2003;300:615–18.
17. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. *Cancer Res* 1991;51:4187–91.
18. Slater R, Radstone D, Matthews L, McDaid J, Majeed A. Hepatic resection for colorectal liver metastasis after downstaging with irinotecan improves survival. *Proc Am Soc Clin Oncol* 2003;22(abstract 1287).
19. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. *Jpn J Cancer Res* 1993;84:697–702.
20. Atsumi R, Suzuki W, Hokusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. *Xenobiotica* 1991;21:1159–69.
21. Onda T, Nakamura I, Seno C, Matsumoto S, Kitagawa M, Okamoto K, Nishikawa K, Suzuki M. Superior antitumor activity of NK012, 7-ethyl-10-hydroxycamptoyhecin-incorporating micellar nanoparticle, to irinotecan. *Proc Am Assoc Cancer Res* 2006;47:720s(abstract 3062).
22. Tourmignand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 2004;22:229–37.
23. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. *J Clin Oncol* 2005;23:4866–75.

ORIGINAL ARTICLE

Toshiro Nishida · Kuniaki Shirao · Akira Sawaki  
Masato Koseki · Takeshi Okamura · Atsushi Ohtsu  
Toshiro Sugiyama · Kuniyoshi Miyakawa · Seiichi Hirota

## Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (ST1571B1202)

Received: March 27, 2007 / Accepted: November 8, 2007

### Abstract

**Background.** Imatinib mesylate, an inhibitor of KIT, ABL protein, and platelet-derived growth factor receptor  $\alpha$  (PDGFR $\alpha$ ) tyrosine kinase, has recently been found to have a dramatic antitumor effect on gastrointestinal stromal tumor (GIST). The aim of this study was to assess the efficacy and safety of imatinib mesylate in Japanese patients with advanced GIST.

**Methods.** Patients with measurable lesions were enrolled between April 1, 2002, and September 20, 2002, using a design based on previous phase II studies in the United

States and the European Union. The diagnosis of GIST was proven histologically with positive immunostaining for KIT (CD117). Imatinib mesylate was administered at a dose of either 400 mg or 600 mg once a day. Pharmacokinetic parameters and mutation analysis of *c-kit* were also assessed in a subgroup of patients.

**Results.** A total of 74 patients (28 receiving imatinib mesylate at 400 mg/day; 46 receiving 600 mg/day); median age, 56.0 years, were enrolled. No patient had a complete response. 51 patients (69%) had a partial response, and 19 patients (26%) had stable disease. The median progression-free survival time was 96 weeks. The estimated 3-year overall survival (Kaplan-Meier) rate for all patients was 73.6%. The most frequent adverse effects related to the drug were nausea (78%), diarrhea (70%), dermatitis (62%), facial edema (61%), edema of the lower limbs (58%), vomiting (54%), and eyelid edema (51%). Most of the adverse effects were mild and manageable.

**Conclusion.** Imatinib mesylate is generally safe and has significant activity in the treatment of advanced GIST in Japanese patients.

**Key words** Gastrointestinal stromal tumor · Imatinib · Phase II

T. Nishida\* (✉)  
Department of Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan  
Tel. + 81-6-879-3153; Fax + 81-6-879-3163  
e-mail: toshin@surg1.med.osaka-u.ac.jp

K. Shirao\*  
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

A. Sawaki\*  
Department of Gastroenterology, Aichi Cancer Center Hospital, Aichi, Japan

M. Koseki\*  
Department of Surgery, National Hospital Organization Kure Medical Center, Hiroshima, Japan

T. Okamura  
Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan

A. Ohtsu\*  
Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East, Chiba, Japan

T. Sugiyama\*  
Department of Gastroenterology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan

K. Miyakawa  
Diagnostic Radiology Division, National Cancer Center Hospital, Tokyo, Japan

S. Hirota\*  
Department of Surgical Pathology, Hyogo College of Medicine, Hyogo, Japan

\*Japanese Study Group on GIST

### Introduction

Gastrointestinal stromal tumor (GIST), the most common mesenchymal tumor in the gut, is generally considered to be malignant, with different degrees of clinicopathological aggressiveness.<sup>1</sup> Although surgery is the mainstay of therapy for GIST, there are still cases of primary unresectable advanced GIST, and GIST frequently relapses even after apparently complete resection. After recurrence, conventional chemotherapy or radiotherapy is ineffective, and the median survival of patients with a relapse of GIST has been estimated to be almost 1 year.<sup>2</sup> Until recently, the prognosis of patients with advanced or metastatic GIST was dismal.

Gain-of-function mutations of the *c-kit* gene or the platelet-derived growth factor receptor  $\alpha$  (*PDGFR $\alpha$* ) gene are found in sporadic as well as in familial GISTs and are thought to be causative factors for GIST.<sup>3,4</sup> GIST usually expresses the KIT protein, with fewer than 5% of GISTs being immunohistochemically negative for this protein. In the latter cases, patients usually have mutations in the *PDGFR $\alpha$*  gene. Constitutively activated KIT or *PDGFR $\alpha$*  plays a central role in the pathogenesis as well as progression of GIST tumor cells.<sup>3-7</sup> Imatinib mesylate, a selective tyrosine kinase inhibitor of BCR-ABL, KIT, and *PDGFR* proteins, has had a significant impact in the treatment of chronic myeloid leukemia (CML).<sup>8</sup> Early reports of clinical trials in the United States and the European Union have also shown that the drug is active against advanced and/or metastatic GIST.<sup>9-11</sup> Based on this evidence, we conducted a phase II study to evaluate the efficacy, safety, and pharmacokinetics of imatinib mesylate in Japanese patients with unresectable and/or metastatic GIST.

## Patients and methods

### Patients

Eligibility criteria required patients aged between 20 and 75 years of age with histologically proven KIT (CD117)-positive unresectable or metastatic GIST. Before study entry, the pathological specimens were reviewed centrally by a single pathologist.

Inclusion criteria also included the following: at least one measurable and previously untreated lesion detected by computed tomographic (CT) scan or magnetic resonance imaging (MRI), an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, adequate organ function, as follows: neutrophils 1500/ $\mu$ l or more, platelets 100 000/ $\mu$ l or more, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) within 2.5 times the upper limit of normal (ULN; 5  $\times$  ULN with liver metastasis), bilirubin less than 1.5  $\times$  ULN, creatinine less than 1.5  $\times$  ULN, a life expectancy of at least 2 months, and written informed consent. Patients were not allowed to receive any chemotherapy, surgery, or radiotherapy for at least 4 weeks before study entry. This study was performed at seven medical centers in Japan after approval by each institutional review board.

### Treatment schedule

The initial 28 patients, who were enrolled between April 1, 2002, and June 7, 2002, were assigned to take 400 mg imatinib mesylate. However, after a United States Food and Drug Administration (FDA) review, the recommended dose in the United States was changed from 400 mg to 400 mg or 600 mg. Accordingly, a 600-mg cohort was added to the protocol, and 46 patients, who were enrolled between June 28, 2002, and September 20, 2002, were assigned to

take 600 mg imatinib mesylate once daily. The drug was taken within 2 h after a meal.

Dose escalation to 800 mg was allowed if the tumor progressed and the patients tolerated the initial dose. Patients whose tumors progressed despite the dose increment were withdrawn from the study.

### Evaluation of response and toxicity

The response of the tumor to imatinib was evaluated after 1 month, after 3 months, and every 3 months thereafter, or whenever medically indicated. Assessments were performed according to the standard Southwest Oncology Group (SWOG) criteria and were based solely on CT or MRI findings. Responses were classified as follows: complete response (CR; disappearance of all disease that could be measured and evaluated); partial response (PR; >50% decrease in the sum of the products of the perpendicular diameters of all measurable lesions, absence of progression, and absence of new lesions); stable disease (SD; a response that did not qualify as a CR, a PR, or progressive disease); or progressive disease (PD; a >50% increase, or an increase of >10 cm<sup>2</sup> [whichever was smaller] in the sum of the products of the perpendicular diameters of all measurable lesions, worsening of a lesion that could be evaluated, the reappearance of any lesion, the presence of a new lesion, or failure of the patient to return for evaluation because of a deteriorating condition).

Toxic effects were recorded in accordance with the National Cancer Institute Common Toxicity Criteria version 2.

### Pharmacokinetics

For pharmacokinetic analysis, blood samples were obtained from 21 patients hospitalized in the two hospitals (National Cancer Center Hospital and National Cancer Center Hospital East). Plasma samples were collected before, and 1, 2, 3, 8, 24, 48, and 72 h after administration of the agent on day 1 and before, 1, 2, 3, 8, and 24 h after administration of the agent on day 29. Plasma imatinib and CGP74588 (a major metabolite of imatinib) concentrations were determined by a liquid chromatography/tandem mass spectrometry assay.<sup>12</sup> Pharmacokinetic parameters were calculated by means of noncompartmental analysis.

### Immunohistochemical and genetic analyses

Immunohistochemical and genetic analyses were performed on paraffin-embedded sections of formalin-fixed tissues. Immunohistochemical analysis for the detection of KIT (CD117) was performed using a polyclonal rabbit antibody (A4502; DAKO, Kyoto, Japan) and the Envision method with antigen retrieval.<sup>13</sup> Tumor specimens from patients were analyzed for *c-kit* mutations of exon 9, 11, 13, or 17, using polymerase chain reaction (PCR) amplification of genomic DNA and direct DNA sequencing.<sup>13</sup> This approach

was validated by comparison with reverse transcriptase (RT)-PCR sequencing of the entire *c-kit* coding sequence in a subset of patients. These laboratory studies were performed under the guidelines for genetic analysis of each institution, and written informed consent for genetic analysis was obtained from all participants.

#### Statistics

The primary endpoint of this study was the response rate, and secondary endpoints were safety and pharmacokinetics. Originally, a sample size in the 400-mg-group of at least 15 evaluable patients per arm was determined based on a Fleming single-stage procedure under conditions of  $P_0 = 5\%$ ,  $P_1 = 32\%$ ,  $\alpha = 2.5\%$  (one sided) and  $\text{power} = 90\%$ . With these sample sizes, the widths of the 95% confidence interval were no more than  $\pm 20\%$  and  $\pm 15\%$ , respectively. Progression-free survival (PFS) was analyzed as time-to-event data for all patients. The starting date for PFS was the date of the first dose. The earliest occurrence of any progression, or death due to any cause, was used as the PFS. Patients, who had neither progressed, died, nor discontinued from the trial for any reason other than "condition no longer requires therapy", were censored for analysis at the time of their last tumor assessment. Overall survival (OS) was analyzed as time-to-event for all patients. The start date was the first date of study medication. The date of death was included in follow-up data. Patients who did not die were censored at the last date they were known to be alive.

All analyses were performed using Statistical Analysis Software (version 8.0; SAS Institute, Cary, NC, USA), and a value of  $P < 0.05$  was considered significant.

## Results

#### Demographics

Between April 1, 2002, and September 20, 2002, 81 patients were recruited for this study, and of these, 74 patients with positive immunoreactivity for KIT protein by central pathological review were registered. There were 48 men and 26 women, with a median age of 56 years (range, 24 to 74 years; Table 1). Twenty-eight patients received initial daily doses of 400 mg of imatinib and 46 patients received 600 mg daily. Sixty-seven (91%) and 20 (27%) patients had a prior history of surgery and chemotherapy, respectively, while no patient had had radiotherapy. Patients who had previously undergone chemotherapy had received between one and five courses.

The primary site of the GIST was the esophagus ( $n = 2$ ), stomach ( $n = 33$ ), small intestine ( $n = 34$ ), colon ( $n = 2$ ), or elsewhere ( $n = 3$ ). Metastatic/relapse sites at registration (some patients have multiple metastatic/relapse sites) were the liver ( $n = 52$ ), peritoneum ( $n = 38$ ), local ( $n = 12$ ), lung ( $n = 6$ ), skin ( $n = 3$ ), bone ( $n = 2$ ), and adrenal gland ( $n = 2$ ).

#### Pharmacokinetics

The pharmacokinetics of imatinib was evaluated in 21 patients on day 1 and on day 29 (Table 2). The plasma concentration of imatinib reached a peak approximately 3 to 6 h after oral administration, and then declined in a monophasic manner with a half-life of 16 to 18 h. On day 1, maximum concentration ( $C_{\text{max}}$ ) values were 2.51 and

**Table 1.** Patient demographics

Demographics	400 mg ( $n = 28$ )	600 mg ( $n = 46$ )	Either dose ( $n = 74$ )
Age (years)			
Median	54.0	56.5	56.0
Range	24–70	33–74	24–74
Sex, $n$ (%)			
Male	19 (67.9)	29 (63.0)	48 (64.9)
Female	9 (32.1)	17 (37.0)	26 (35.1)
ECOG performance status, $n$ (%) <sup>a</sup>			
0	22 (78.6)	35 (76.1)	57 (77.0)
1	6 (21.4)	8 (17.4)	14 (18.9)
2	0	3 (6.5)	3 (4.1)
Primary site of tumor, $n$ (%)			
Esophagus	1 (3.6)	1 (2.2)	2 (2.7)
Stomach	11 (39.3)	22 (47.8)	33 (44.6)
Intestine	14 (50.0)	20 (43.5)	34 (45.9)
Colon	2 (7.1)	0	2 (2.7)
Others	0	3 (6.5)	3 (4.1)
Previous treatment, $n$ (%)			
Surgery	25 (89.3)	42 (91.3)	67 (90.5)
Chemotherapy	8 (28.6)	12 (26.0)	20 (27.0)
Radiotherapy	0	0	0

<sup>a</sup>ECOG, Eastern Cooperative Oncology Group

**Table 2.** Pharmacokinetic (PK) parameters of imatinib in GIST patients on day 1 and day 29 following once-daily oral administration of imatinib at doses of 400mg and 600mg

PK parameter	Mean ± SD (Range)	
	400mg (n = 9)	600mg (n = 12)
<b>Day 1</b>		
T <sub>max</sub> (h)	3.23 ± 1.91 (1.10–8.00)	6.36 ± 2.48 (2.97–8.17)
C <sub>max</sub> (µg/ml)	2.51 ± 1.00 (1.29–3.78)	3.45 ± 2.20 (1.38–7.65)
AUC <sub>0–24</sub> (µg <sup>2</sup> h/ml)	34.7 ± 13.6 (13.7–53.0)	56.1 ± 40.8 (21.5–141)
t <sub>1/2</sub> (h)	15.5 ± 1.9 (12.7–18.2)	18.2 ± 4.6 (11.8–28.1)
<b>Day 29<sup>a</sup></b>		
T <sub>max</sub> (h)	3.24 ± 2.05 <sup>b</sup> (1.00–8.00)	3.61 ± 2.02 <sup>c</sup> (1.92–8.08)
C <sub>max</sub> (µg/ml)	2.86 ± 0.87 <sup>b</sup> (1.77–4.27)	3.11 ± 0.65 <sup>c</sup> (2.30–4.37)
AUC <sub>0–24</sub> (µg <sup>2</sup> h/ml)	47.6 ± 17.0 <sup>b</sup> (16.1–73.8)	58.9 ± 11.7 <sup>c</sup> (45.9–75.5)
t <sub>1/2</sub> (h)	20.0 ± 4.9 <sup>b</sup> (9.10–25.6)	25.5 ± 8.4 <sup>d</sup> (17.8–40.5)
<b>Accumulation ratio (Day 29/Day 1)</b>		
C <sub>max</sub>	1.2 ± 0.6 <sup>b</sup> (0.67–2.6)	1.5 ± 0.4 <sup>c</sup> (0.94–2.2)
AUC <sub>0–24</sub>	1.4 ± 0.5 <sup>b</sup> (0.90–2.3)	1.8 ± 0.5 <sup>c</sup> (1.2–2.5)

<sup>a</sup>Days 28 to 31

<sup>b</sup>n = 8

<sup>c</sup>n = 7

<sup>d</sup>n = 6

**Table 3.** Confirmed best responses to imatinib in patients with GIST

Best response	N (% [95% CI])		
	400mg (n = 28)	600mg (n = 46)	Either dose (n = 74)
Complete response	0	0	0
Partial response	17 (60.7 [40.6–78.5])	34 (73.9 [58.9–85.7])	51 (68.9 [57.1–79.1])
Stable disease	11 (39.3 [21.5–59.4])	8 (17.4 [7.8–31.4])	19 (25.7 [16.2–37.2])
Progressive disease	0	2 (4.3)	2 (2.7)
Not evaluated	0	2 (4.3)	2 (2.7)


CI, Confidence interval

3.45µg/ml in the 400-mg and 600-mg dose groups, respectively. Although there was some interpatient variability, dose-dependency was observed for AUC and C<sub>max</sub>. After repeated administrations, accumulation of imatinib was observed, and the AUC was 1.4 to 1.8-fold higher than after the first dose. This accumulation ratio corresponded well to the value estimated from half-lives on day 1, i.e., a 1.5- to 1.7-fold accumulation.

### Efficacy

Of the 74 patients registered, 51 patients (69%) achieved a PR, 19 patients (26%) had SD, and 2 patients had PD, while no CR was observed (Table 3). All the PRs were confirmed by repeated imaging after at least 28 days. Although the median time to response was 12 weeks, the cumulative incidence of response (Fig. 1) showed that 3 patients achieved a clinical response after 48 weeks.

Disease progression during treatment occurred in 48 patients, 34 of whom were withdrawn from the study. Two patients died during the study, and a follow-up after study discontinuation indicated that 20 further patients had died. The median PFS of all patients was 96 weeks (Fig. 2). There was no significant difference between the two dose-groups (400-mg vs 600-mg) in the intention-to-treat analysis Log-



**Fig. 1.** Cumulative incidence of response by dose level of imatinib. Cumulative response incidence of the 400-mg dose group (solid line), 600-mg dose group (dotted line), and either dose group (dashed line) are shown

rank  $P = 0.1943$ ). The estimated 3-year overall survival (Kaplan-Meier) rate for all patients was 73.6%. Median survival time was not reached during the study (Fig. 3). It could not be said that the OS of the 600mg dose-group was better than that of the 400mg dose-group (log-rank  $P = 0.0679$ ).





Fig. 2. Kaplan-Meier estimates of progression free survival (PFS) by dose level of imatinib. The PFS times of the 400-mg dose group (solid line), 600-mg dose group (dotted line), and either dose group (dashed line) are shown. The median PFS of the 400-mg dose group (74.1 weeks) was not significantly different from that of the 600-mg dose group (107.3 weeks; log-rank  $P = 0.1943$ )



Risk sets of Kaplan-Meier plot (Overall survival)						
Day	200	400	600	800	1000	1200
400 mg	28	26	23	21	18	4
600 mg	44	44	43	41	36	0
Either dose	72	70	66	62	54	4

Fig. 3. Kaplan-Meier estimates of overall survival (OS) times by dose level of imatinib. The OS of the 400-mg dose group (solid line), 600-mg dose group (dotted line), and either dose group (dashed line) are shown. There was no significant difference in the overall survival rates of the two dose groups (log-rank  $P = 0.1679$ )

#### Safety

In this study, imatinib was generally well tolerated. Although all patients had adverse effects related to the drug (Table 4), most of these effects were of grades 1 or 2. The most frequently affected systems were the skin and subcutaneous tissue (94.6%), gastrointestinal system (91.9%), and general disorders and administration-site conditions (85.1%). Troublesome symptoms included nausea not otherwise specified (NOS; 78.4%), diarrhea NOS (70.3%), dermatitis NOS (62.2%), facial edema (60.8%), edema of the lower limbs (58.1%), vomiting NOS (54.1%), and eyelid edema (51.4%). Grade 3 or 4 adverse effects occurred in 40 patients (54.1%) and the most frequent were neutropenia (21.6%), anemia




Fig. 4. Kaplan-Meier estimates of progression-free survival (PFS) by kinase genotype. Patients with gastrointestinal stromal tumor (GIST) with KIT mutations in exon 11 or exon 13 (solid line) showed significantly better PFS than those with KIT mutations in exon 9 or no mutation (dotted line; log-rank  $P = 0.0014$ )

NOS (17.6%), dermatitis NOS (6.8%), and anorexia (5.4%). A total of 8 patients (10.8%) were reported as having gastrointestinal or intratumoral hemorrhage, which included tumor hemorrhage (6.8%), intraperitoneal hemorrhage (4.1%), gastrointestinal hemorrhage NOS (2.7%), and melena (2.7%). There was no evidence of tumor lysis syndrome, even in patients with very rapid decreases in tumor volume.

#### Genetic analysis

Somatic mutation analyses were available in 58 patients. In others, this could not be performed because of lack of amplification products by PCR. Among the 58 tumors, *c-kit* gene mutations were found in 53, including 48 in exon 11, 4 in exon 9, and 1 in exon 13 (Table 5). Five patients had no mutation in the *c-kit* gene. The proportions of mutations found in each exon were similar to those in previous reports.<sup>14</sup> Subgroup analysis of tumor response according to the *c-kit* genotype indicated that 39 (81%) of the 48 patients with exon 11 mutations achieved a PR, while 2 (50%) of the 4 patients with an exon 9 mutation showed a PR. None of the 5 patients who had no mutation in the *c-kit* gene achieved a PR (Table 5).

As shown in Fig. 4, the median PFS in patients with exon 11 or 13 mutations (median PFS, 108 weeks) was significantly longer than that in patients with exon 9 or no mutations (75 weeks; log-rank  $P = 0.0014$ ).

#### Discussion

Most GISTs are caused by gain-of-function mutations of the *c-kit* or *PDGFR $\alpha$*  genes, which induce tumor-cell proliferation.<sup>13-7</sup> Imatinib mesylate efficiently inhibits BCR-ABL, KIT, and PDGFR $\alpha$  proteins *in vitro*, and is clinically active against GIST and CML, which express mutated KIT and/or



**Table 4.** Adverse effects possibly related to imatinib

	n (%)					
	Any grade			Grade 3 or 4		
	400mg (n = 28)	600mg (n = 46)	Either dose (n = 74)	400mg (n = 28)	600mg (n = 46)	Either dose (n = 74)
Any adverse effect possibly related to the study drug	28 (100.0)	46 (100.0)	74 (100.0)	13 (46.4)	27 (58.7)	40 (54.1)
Skin and subcutaneous tissue disorders	25 (89.3)	45 (97.8)	70 (94.6)	1 (3.6)	6 (13.0)	7 (9.5)
Dermatitis NOS <sup>a</sup>	15 (53.6)	31 (67.4)	46 (62.2)	0	5 (10.9)	5 (6.8)
Facial edema	16 (57.1)	29 (63.0)	45 (60.8)	1 (3.6)	1 (2.2)	2 (2.7)
Eyelid edema	14 (50.0)	24 (52.2)	38 (51.4)	1 (3.6)	0	1 (1.4)
Periorbital edema	5 (17.9)	8 (17.4)	13 (17.6)	0	0	0
Alopecia	1 (3.6)	9 (19.6)	10 (13.5)	0	0	0
Pigmentation disorder NOS <sup>a</sup>	2 (7.1)	8 (17.4)	10 (13.5)	0	0	0
Pruritus NOS <sup>a</sup>	2 (7.1)	8 (17.4)	10 (13.5)	0	0	0
Skin discoloration	1 (3.6)	6 (13.0)	7 (9.5)	0	0	0
Hemorrhage, subcutaneous	3 (10.7)	2 (4.3)	5 (6.8)	0	0	0
Gastrointestinal disorders	27 (96.4)	41 (89.1)	68 (91.9)	6 (21.4)	6 (13.0)	12 (16.2)
Nausea NOS <sup>a</sup>	21 (75.0)	37 (80.4)	58 (78.4)	1 (3.6)	1 (2.2)	2 (2.7)
Diarrhea NOS <sup>a</sup>	20 (71.4)	32 (69.6)	52 (70.3)	0	2 (4.3)	2 (2.7)
Vomiting NOS <sup>a</sup>	16 (57.1)	24 (52.2)	40 (54.1)	1 (3.6)	1 (2.2)	2 (2.7)
Abdominal pain NOS <sup>a</sup>	8 (28.6)	11 (23.9)	19 (25.7)	2 (7.1)	0	2 (2.7)
Flatulence	9 (32.1)	9 (19.6)	18 (24.3)	0	0	0
Ascites	4 (14.3)	5 (10.9)	9 (12.2)	1 (3.6)	0	1 (1.4)
Abdominal distension	4 (14.3)	4 (8.7)	8 (10.8)	0	0	0
Stomatitis	2 (7.1)	6 (13.0)	8 (10.8)	0	0	0
Abdominal pain, upper	1 (3.6)	5 (10.9)	6 (8.1)	0	0	0
Constipation	1 (3.6)	5 (10.9)	6 (8.1)	0	0	0
Loose stools	3 (10.7)	2 (4.3)	5 (6.8)	0	0	0
General disorders and administration-site conditions	25 (89.3)	38 (82.6)	63 (85.1)	3 (10.7)	5 (10.9)	8 (10.8)
Edema, lower limb	19 (67.9)	24 (52.2)	43 (58.1)	0	1 (2.2)	1 (1.4)
Malaise	8 (28.6)	18 (39.1)	26 (35.1)	0	1 (2.2)	1 (1.4)
Edema NOS <sup>a</sup>	7 (25.0)	16 (34.8)	23 (31.1)	0	1 (2.2)	1 (1.4)
Fatigue	9 (32.1)	12 (26.1)	21 (28.4)	1 (3.6)	1 (2.2)	2 (2.7)
Pyrexia	3 (10.7)	2 (4.3)	5 (6.8)	1 (3.6)	0	1 (1.4)
Musculoskeletal and connective tissue disorders	14 (50.0)	30 (65.2)	44 (59.5)	0	1 (2.2)	1 (1.4)
Muscle cramps	12 (42.9)	24 (52.2)	36 (48.6)	0	0	0
Arthralgia	4 (14.3)	4 (8.7)	8 (10.8)	0	0	0
Myalgia	0	6 (13.0)	6 (8.1)	0	0	0
Blood and lymphatic system disorders	10 (35.7)	22 (47.8)	32 (43.2)	7 (25.0)	20 (43.5)	27 (36.5)
Neutropenia	4 (14.3)	16 (34.8)	20 (27.0)	3 (10.7)	13 (28.3)	16 (21.6)
Anemia NOS <sup>a</sup>	6 (21.4)	9 (19.6)	15 (20.3)	5 (17.9)	8 (17.4)	13 (17.6)
Eye disorders	7 (25.0)	21 (45.7)	28 (37.8)	0	0	0
Lacrimation, increased	1 (3.6)	11 (23.9)	12 (16.2)	0	0	0
Eye redness	3 (10.7)	4 (8.7)	7 (9.5)	0	0	0
Metabolic and nutritional disorders	9 (32.1)	17 (37.0)	26 (35.1)	3 (10.7)	3 (6.5)	6 (8.1)
Anorexia	6 (21.4)	15 (32.6)	21 (28.4)	2 (7.1)	2 (4.3)	4 (5.4)
Nervous system disorders	7 (25.0)	15 (32.6)	22 (29.7)	0	0	0
Headache NOS <sup>a</sup>	4 (14.3)	4 (8.7)	8 (10.8)	0	0	0
Dysgeusia	1 (3.6)	5 (10.9)	6 (8.1)	0	0	0
Respiratory, thoracic, and mediastinal disorders	3 (10.7)	9 (19.6)	12 (16.2)	0	1 (2.2)	1 (1.4)
Pleural effusion	2 (7.1)	7 (15.2)	9 (12.2)	0	0	0

Data are for categories of events that occurred in at least 10 % of the patients in at least one of the two groups

<sup>a</sup>NOS, not otherwise specified

**Table 5.** Correlation of tumor response by kinase genotype

	Best response n (%)			
	Exon 9 (n = 4)	Exon 11 (n = 48)	Exon 13 (n = 1)	No mutation (n = 5)
Complete response	0	0	0	0
Partial response	2 (50.0)	39 (81.3)	1 (100)	0
Stable disease	2 (50.0)	8 (16.7)	0	4 (80.0)
Progressive disease	0	1 (2.1)	0	1 (20.0)

PDGFR $\alpha$ , and BCR-ABL proteins, respectively.<sup>5-8</sup> Imatinib has potent antiproliferative and apoptotic effects on GIST cells.<sup>10,15,16</sup> Studies in the United States and Europe have shown that 5% of GIST patients show a CR; 45%–54%, a PR; and 24%–28%, SD.<sup>10,17</sup> Recent update data from a European Union-United States study suggest that the response fraction may be increased with prolonged use of imatinib: two patients (1%) achieved a complete response; 67%, a PR; and 16%, SD.<sup>15</sup> Although no objective reduction of tumor size was reported in patients with SD, the treatment was beneficial in maintaining disease stability for more than several months in the majority of patients, and in increasing survival. In fact, the study indicated that the 4-year overall survival rate of patients with a PR (62%) was similar to that of patients with SD (64%). High-dose imatinib (800 mg/day) has been shown to provide longer progression-free survival (PFS) than the conventional dose (400 mg/day).<sup>17</sup> In the present study, the two dose groups (400 mg/day and 600 mg/day) did not show significant differences in either PFS or overall survival (OS).

In the present study, 69% of Japanese patients with advanced and/or metastatic GIST treated with imatinib had a confirmed PR, and 26% had SD. The median time to response was 12 weeks. The median PFS was 96 weeks and the estimated 3 year OS (Kaplan-Meier) rate for all patients was 73.6%. These efficacy results obtained in Japanese patients are very similar to those previously obtained in Caucasians.<sup>10,17,18</sup> Furthermore, sunitinib malate, an oral multitargeted tyrosine kinase receptor inhibitor, was developed and has been evaluated in patients with imatinib-resistant GIST and in patients who could not tolerate imatinib. A recent study has shown that the drug has significant clinical activities in imatinib-resistant GIST, with acceptable tolerability.<sup>19</sup>

In vitro, the inhibitory activity of imatinib on wild-type and mutated KIT and PDGFR $\alpha$  kinases depends on mutational status.<sup>15,16</sup> The clinical response to the drug has also been shown to be related to the mutation status of the *c-kit* and *PDGFR $\alpha$*  genes.<sup>14</sup> In the present study, imatinib was most effective for GIST patients with exon 11 mutations in the *c-kit* gene, followed by those with exon 9 mutations, then by those with no *c-kit* mutation. Patients with either exon 11 or exon 13 mutations had a significantly superior PFS compared with those who had exon 9 mutation or no mutation.

In the present study, imatinib was well tolerated, especially compared with conventional chemotherapy. The adverse events probably due to the drug were generally limited to nonserious (grade 1 or 2) cases of nausea, diarrhea, dermatitis, facial edema, edema of the lower limbs, vomiting, or eyelid edema. No difference in adverse events between the dose groups was shown in this study. Severe adverse effects (grade 3 or 4) included neutropenia (21.6%), anemia NOS (17.6%), dermatitis NOS (6.8%), and anorexia (5.4%). A total of eight patients (10.8%) were reported as having gastrointestinal or intratumoral hemorrhage. The hemorrhage may have been caused by the study drug through the following mechanisms: (1) direct local irritation of the gastrointestinal tract, (2) a systemic effect via throm-

bocytopenia, or (3) breakdown of tumor-associated blood vessels concomitant with tumor-cell death.

In our study, imatinib was detectable in the blood soon after oral intake, with a mean half-life of 18h, and blood levels of imatinib and its metabolites appeared to be dose-dependent in a dose range between 400 and 600 mg/day. The median weight and body surface area of our Japanese patients were 56.4 kg (range, 35.9–95.8 kg) and 1.59 m<sup>2</sup> (range, 1.23–2.15 m<sup>2</sup>), values which were less than those of the corresponding parameters in Caucasians, but the pharmacokinetic data in our patients were similar to those obtained in United States and European Union clinical trials.<sup>10,21</sup> This suggests that body weight does not have a major influence on the plasma concentration of the drug, in accordance with findings described elsewhere.<sup>21</sup> No clear correlation was observed between C<sub>max</sub>/AUC and body weight in our study.

In summary, imatinib has positive therapeutic effects in Japanese patients with unresectable and/or metastatic GIST, and it is safe and well tolerated. Its pharmacokinetic parameters are similar to those in Caucasians. The inhibitory activity of imatinib on the KIT and PDGFR $\alpha$ -signaling pathways depends on the genotype of the *c-kit* and *PDGFR $\alpha$*  genes, and imatinib mesylate provides a promising treatment modality for advanced GIST.

**Acknowledgments** The authors are grateful to the many investigators involved in this clinical trial, who include Shusaku Tsutsui<sup>1</sup>, Yasuhide Yamada<sup>2\*</sup>, Kenji Yamao<sup>3\*</sup>, Masahiko Taniguchi<sup>4</sup>, Yasushi Toh<sup>5</sup>, Toshihiko Doi<sup>6\*</sup>, and Yoshito Komatsu<sup>7\*</sup>. We also wish to thank Novartis Pharma K.K.

<sup>1</sup>Department of Internal Medicine, Osaka University Graduate School of Medicine; <sup>2</sup>Department of Medical Oncology, National Cancer Center Hospital; <sup>3</sup>Department of Gastroenterology, Aichi Cancer Center Hospital; <sup>4</sup>Department of Surgery, National Hospital Organization Kure Medical Center; <sup>5</sup>Department of Gastroenterological Surgery, National Kyusyu Cancer Center; <sup>6</sup>Division of Gastrointestinal Oncology/Digestive Endoscopy, National Cancer Center Hospital East; <sup>7</sup>Department of Gastroenterology, Hokkaido University Graduate School of Medicine, and <sup>8</sup>The Japanese Study Group on GIST.

## References

1. Nishida T, Hirota S (2000) Biological and clinical review of stromal tumors in the gastrointestinal tract. *Histol Histopathol* 15: 1293–1301
2. DeMatteo RP, Heinrich MC, El-Rifai WM, et al. (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. *Hum Pathol* 33:466–477
3. Kitamura Y, Hirota S, Nishida T (2003) Gastrointestinal stromal tumor (GIST): a model for molecule-based diagnosis and treatment of solid tumors. *Cancer Sci* 94:315–320
4. Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. *J Clin Oncol* 22:3813–3825
5. Hirota S, Isozaki K, Moriyama Y, et al. (1998) Gain-of-function mutation of *c-kit* in human gastrointestinal stromal tumors. *Science* 279:577–580
6. Heinrich MC, Corless CL, Duensing A, et al. (2003) PDGFR $\alpha$  activating mutations in gastrointestinal stromal tumors. *Science* 299:708–710
7. Hirota S, Ohashi A, Nishida T, et al. (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene as another cause of human gastrointestinal stromal tumors. *Gastroenterology* 125:660–667

8. Druker BJ, Talpaz M, Resta DJ, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med* 344:1031-1037
9. van Oosterom AT, Judson I, Verweij J, et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. *Lancet* 358:1421-1423
10. Demetri GD, von Mehren M, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 347:472-480
11. Verweij J, van Oosterom A, Blay JY, et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumors, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. *Eur J Cancer* 39:2006-2011
12. Bakhtiar R, Lohne JL, Ramos L, et al. (2002) High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. *J Chromatogr B Biomed Appl* 768:325-340
13. Hirota S, Nishida T, Isozaki K, et al. (2002) Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. *Gastroenterology* 122:1493-1499
14. Heinrich MC, Corless CL, Demetri GD, et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol* 21:4342-4349
15. Chen H, Isozaki K, Kinoshita K, et al. (2003) Imatinib inhibits various types of activating mutant *kit* found in gastrointestinal stromal tumors. *Int J Cancer* 105:130-135
16. Ohashi A, Kinoshita K, Isozaki K, et al. (2004) Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha. *Int J Cancer* 111:317-321
17. Verweij J, Casali PG, Zalcberg J, et al. (2004) Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. *Lancet* 364:1127-1134
18. Blanke CD, Demetri GD, Mehren MV, et al. (2006) Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. *J Clin Oncol* 24:185 (Suppl: abstract 9825)
19. Demetri GD, van Oosterom AT, Garrett CR, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet* 368:1329-1338
20. Judson I, Ma P, Peng B, et al. (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumor: a retrospective population pharmacokinetic study over time. *EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol* 55:379-386
21. Dagher R, Cohen M, Williams G, et al. (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. *Clin Cancer Res* 8:3034-3038

## Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer

Junichi Matsubara,<sup>1</sup> Yasuhide Yamada,<sup>1</sup> Yoshinori Hirashima,<sup>1</sup> Daisuke Takahari,<sup>1</sup> Natsuko T. Okita,<sup>1</sup> Ken Kato,<sup>1</sup> Tetsuya Hamaguchi,<sup>1</sup> Kuniaki Shirao,<sup>1</sup> Yasuhiro Shimada,<sup>1</sup> and Tadakazu Shimoda<sup>2</sup>

**Abstract Purpose:** Expression levels of insulin-like growth factor type 1 receptor (IGF-IR), epidermal growth factor receptor (EGFR), and HER2 expressions have been linked to clinical outcomes in several solid tumors. However, the clinical significance of these biomarkers in gastric cancer (GC) remains unclear. This study was designed to delineate the clinical implications of these three biomarkers in GC.

**Experimental Design:** The study group comprised 87 patients who underwent gastrectomy at National Cancer Center Hospital and subsequently received chemotherapy for recurrent or residual tumors. Using immunohistochemical techniques, we analyzed the expressions of IGF-IR, EGFR, and HER2 on formalin-fixed paraffin-embedded specimens of surgically removed primary tumors.

**Results:** IGF-IR expression (defined as >10% membranous staining) was found in 67 tumors (77%), EGFR expression in 55 (63%), and HER2 expression in 16 (18%). Positive coexpression of IGF-IR and EGFR was found in 48 tumors (55%), that of IGF-IR and HER2 in 16 (18%), and that of EGFR and HER2 in 13 (15%). Multivariate survival analysis showed that IGF-IR-positive expression [hazard ratio (HR) 2.14, 95% confidence interval (95% CI) 1.20-3.82;  $P = 0.01$ ], performance status 1 or 2 (HR 1.83, 95% CI 1.15-2.91;  $P = 0.01$ ), and diffuse type tumors (HR 1.71; 95% CI 1.08-2.70;  $P = 0.02$ ) were significant predictors of poor survival.

**Conclusions:** IGF-IR expression in surgical GC specimens, poor performance status, and diffuse type tumors are significant predictors of poor outcomes in patients with GC. Our data suggest that anti-IGF-IR strategies may prove valuable in such patients.

Globally, gastric cancer (GC) is the third most prevalent malignancy. Although its incidence is declining, ~930,000 cases are newly diagnosed each year (1). Despite the identification and development of several new classes of anticancer agents, GC remains an aggressive malignancy, with a median survival of 7 to 10 months in patients with metastatic or unresectable disease (2, 3). Once metastatic, GC is incurable, and chemotherapy is palliative. Increasing emphasis on the need for improved techniques for the prediction of treatment response and survival may facilitate the tailoring of chemotherapy and risk-related therapy, resulting in significantly better survival.

Insulin-like growth factor type 1 receptor (IGF-IR) is a cell membrane receptor that is activated by its ligands, IGF-I and IGF-II. IGF-IR participates in cell proliferation, differentiation,

and prevention of apoptosis (4, 5). Because IGF-IR is also involved in malignant transformation (5), development of IGF-IR-directed cancer therapy has been initiated. IGF-IR is frequently overexpressed in human cancers, and the association between IGF-IR expression and outcomes has been assessed for breast cancer and other solid tumors (6, 7). However, IGF-IR expression in GC remains poorly understood.

Previous studies have indicated that IGF-IR can interact with epidermal growth factor receptor (EGFR) to augment the malignant behavior of tumors (8, 9). EGFR and its homologues HER2 (also known as *erbB-2*) are members of the *erbB* gene family. These receptors encode for transmembrane receptor-type tyrosine kinases, for which therapeutic approaches do exist. They play a crucial role in tumor cell proliferation, survival, adhesion, migration, and differentiation and also participate in tumor angiogenesis (10). On ligand stimulation, these receptors form either homodimers or heterodimers, which activate their cytoplasmic domain. Through EGFR, epidermal growth factor and transforming growth factor- $\alpha$  stimulate DNA synthesis and cell growth in various systems, including the gastrointestinal tract (11). HER2 is the preferred co-receptor for the formation of dimers with EGFR, HER3, or HER4; the heterodimers consisting of HER2 and these other receptors have a greater capacity for translating mitogenic signals than the homodimers and act synergistically to promote cellular transformation (12). In many cancers, the expression of

**Authors' Affiliations:** <sup>1</sup>Gastrointestinal Oncology Division and <sup>2</sup>Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan

Received 8/2/07; revised 12/12/07; accepted 2/7/08.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Yasuhide Yamada, 5-1-1 Tsukiji, Chuo-ku, Tokyo 1040045, Japan. Phone: 81-3-3542-2511; Fax: 81-3-3542-3815; E-mail: yayamada@ncc.go.jp.

© 2008 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-07-1898